Platform Study of belantamab mafodotin (GSK2857916) as monotherapy and in combination with anti-cancer treatments in participants with RRMM

Phase 1

• Conditions: Relapsed/Refractory Multiple Myeloma; MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2019-001138-32-DE
• Lead Sponsor: GlaxoSmithKline Research & Development Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-07-11
• Last Update Posted: 8 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 504

Inclusion Criteria

Participants are eligible to be included in the study only if all of the criteria in Section 5.1 and Section 5.2 apply. In addition, participants must fulfil additional inclusion/exclusion criteria for at least 1 partner combination sub-study. Criteria for each individual substudy can be found in the respective sub-study protocol sections.

Age
1. Participant must be 18 years of age inclusiveor older, at the time of signing the informed consent. Note: if country/site age requirements for consent differ, the more stringent (e.g. higher age) restriction will be required for that country/site.

Type of Participant and Disease Characteristics

2. Participants who have histologically or cytologically confirmed diagnosis of MM, as defined by the International Myeloma Working Group(IMWG, [Rajkumar, 2014]).

3. Participants who have been treated with at least 3 prior lines of anti-myeloma treatments including an IMID (eg. lenalidomide), a proteasome inhibitor (eg. bortezomib) and an anti-CD38 monoclonal antibody. Lines of therapy are defined by consensus panel of the International Myeloma Workshop [Rajkumar, 2011a].

4. Participants with a history of autologous stem cell transplant are eligible for study participation provided the following eligibility criteria are met:
a. transplant was >100 days prior to screening
b. no active infection(s)

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

6. Measurable disease defined as at least 1 of the following:
• Serum M-protein =0.5 g/dL (=5 g/L)
• Urine M-protein =200 mg/24 hours
• Serum free light chain (FLC) assay: Involved FLC level =10 mg/dL (=100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65)

7. Have organ system functions as defined by the laboratory assessments in Table 13:

8. Participants who have tested positive for HBcAb can be enrolled if the following criteria are met:
-Serology result: HBcAb+, HbsAg-
-Screening: HBV DNA undetectable
-During study Treatment: monitoring per protocol (section 6.6.5), Initiating antiviral treatment if HBV DNA becomes detectable.

9. All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events [NCI -CTCAE], version 5.0, 2017) must be Grade =1 at the time of screening except for alopecia (any grade), neuropathy (Grade =2), or endocrinopathy managed with replacement therapy (any grade).

10. Participants who are currently receiving physiological doses oral steroids (<10mg/day), inhaled steroids or ophthalmalogical steroids are allowed on the study.

Sex
11. Male or female
Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies (see Appendix 7, Section 17.7 for further details).

a. Male Participants:
Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in the clinical studies.
Male participants are eligible to participate if they agree to the following during the intervention period and for at least 6 months after the last dose of study intervention to allow for clearance of any altered sperm:
Refrain from donating sperm
PLUS either:
• Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent
OR
• Must agree to use contraception/barrier as detailed below
• Agree to use a male con

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

Medical Conditions
1.Symptomatic amyloidosis, active 'polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes' (POEMS) syndrome, current
or past diagnosis of plasma cell leukemia.

2. Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities) that could interfere with participant’s safety, obtaining informed consent, or compliance with study procedures.

3. Current corneal epithelial disease except mild punctate keratopathy

4. Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable chronic liver disease (including Gilbert’s syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if participant otherwise meets entry criteria.

5. Malignancies other than disease under study are excluded, except for any other malignancy from which the participant has been disease-free for more than 2 years and, in the opinion of the principal investigators and GSK Medical Monitor, will not affect the evaluation of the effects of this clinical trial treatment on the currently targeted malignancy (MM).
• Participants with curatively treated non-melanoma skin cancer are not excluded.

6. Evidence of cardiovascular risk including any of the following:
a. QTcF interval =480 msecs (the QT interval values must be corrected for heart rate by Fridericia’s formula [QTcF])
b. Evidence of current clinically significant untreated arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Mobiz Type II) or 3rd degree atrioventricular (AV) block.
c. History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, stenting or bypass grafting, all within three months of Screening.
d.Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system
e. Uncontrolled hypertension
f. Recent (within the past 6 months) history of symptomatic pericarditis.

7. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK’916 (belantamab mafodotin) or any of the components of the study treatment. History of severe hypersensitivity to other mAbs.

8. Active infection requiring antibiotic, antiviral, or antifungal treatment.

9. Known HIV infection.

10. Recent history (within the past 6 months) of acute diverticulitis, inflammatory bowel disease, intra-abdominal abscess, or gastrointestinal obstruction.

11. Presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to first dose of study treatment

12. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment.
Note: Participants with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. Hepatitis RNA testing is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing

Prior/Concomitant Therapy
13. Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect partc

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified